Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP881770.RAxq8pfDxK_awj7OEkkNdoAVHMn_FNlTduxE4_jpkAvZU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP881770.RAxq8pfDxK_awj7OEkkNdoAVHMn_FNlTduxE4_jpkAvZU130_assertion type Assertion NP881770.RAxq8pfDxK_awj7OEkkNdoAVHMn_FNlTduxE4_jpkAvZU130_head.
- NP881770.RAxq8pfDxK_awj7OEkkNdoAVHMn_FNlTduxE4_jpkAvZU130_assertion description "[The anaplastic lymphoma kinase (ALK) inhibitor crizotinib has been used in patients with lung cancer or inflammatory myofibroblastic tumor (IMT), both types harboring ALK fusions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP881770.RAxq8pfDxK_awj7OEkkNdoAVHMn_FNlTduxE4_jpkAvZU130_provenance.
- NP881770.RAxq8pfDxK_awj7OEkkNdoAVHMn_FNlTduxE4_jpkAvZU130_assertion evidence source_evidence_literature NP881770.RAxq8pfDxK_awj7OEkkNdoAVHMn_FNlTduxE4_jpkAvZU130_provenance.
- NP881770.RAxq8pfDxK_awj7OEkkNdoAVHMn_FNlTduxE4_jpkAvZU130_assertion SIO_000772 21430068 NP881770.RAxq8pfDxK_awj7OEkkNdoAVHMn_FNlTduxE4_jpkAvZU130_provenance.
- NP881770.RAxq8pfDxK_awj7OEkkNdoAVHMn_FNlTduxE4_jpkAvZU130_assertion wasDerivedFrom befree-2016 NP881770.RAxq8pfDxK_awj7OEkkNdoAVHMn_FNlTduxE4_jpkAvZU130_provenance.
- NP881770.RAxq8pfDxK_awj7OEkkNdoAVHMn_FNlTduxE4_jpkAvZU130_assertion wasGeneratedBy ECO_0000203 NP881770.RAxq8pfDxK_awj7OEkkNdoAVHMn_FNlTduxE4_jpkAvZU130_provenance.